Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

175.87 +0.03 (+0.02%)
Streaming Delayed Price Updated: 11:45 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
56 57 Next >
News headline image
3 Nasdaq Stocks That Are Up 25% in 3 Months ↗
Should you jump on the bandwagon and buy these surging stocks? 
Via The Motley Fool
News headline image
1 Green Flag and 1 Red Flag for Biogen ↗
Biogen beat the bear market this year. 
Via The Motley Fool
News headline image
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With ↗
A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab. 
Via Benzinga
News headline image
Has This Top Pharma Company Found Its Next Billion-Dollar Product? ↗
Eli LIlly is looking to make waves in an important therapeutic area. 
Via The Motley Fool
News headline image
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease ↗
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
News headline image
Is Biogen Stock a Buy Now? ↗
Its revenue now has a plausible path to doubling, but risks remain high. 
Via The Motley Fool
News headline image
CrowdStrike (CRWD) Stock Sinks on Weak Guidance ↗
CrowdStrike (CRWD) stock is falling on Wednesday following the release of its earnings report for the third quarter of 2022. 
Via InvestorPlace
26 Analysts Have This to Say About Biogen ↗
 
Via Benzinga
News headline image
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
From Biogen Inc.
Via GlobeNewswire
News headline image
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
News headline image
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move ↗
These stocks have climbed by double digits this year. 
Via The Motley Fool
News headline image
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
News headline image
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
News headline image
Why 2023 Could Be a Big Year for Biogen ↗
Investors will soon learn if the company's Alzheimer's treatment gets the green light. 
Via The Motley Fool
News headline image
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
From Biogen Inc.
Via GlobeNewswire
News headline image
Even After This Year’s Melt-Up, Runway Remains for LLY Stock ↗
The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making. 
Via InvestorPlace
News headline image
Can These 2 Stocks Crush the Market Again in 2023? ↗
Both are riding the wave of major clinical wins 
Via The Motley Fool
News headline image
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
News headline image
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate ↗
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). 
Via Benzinga
News headline image
BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen ↗
Biogen (BIIB) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate. 
Via InvestorPlace
News headline image
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's ↗
 
Via Benzinga
News headline image
Biogen Stock Is Surging Today: What's Going On? ↗
Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's 
Via Benzinga
News headline image
Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday ↗
Mizuho cut Alphabet Inc. (NASDAQ: GOOGL) price target from $140 to $135. Mizuho analyst James Lee maintained a Buy rating on the stock. Alphabet shares gained 0.4% to $95.53 in pre-market trading. 
Via Benzinga
News headline image
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors ↗
The update from Eisai suggests there is a benefit question ahead of the companies. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success ↗
Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies. 
Via Investor's Business Daily
News headline image
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall ↗
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that... 
Via Benzinga
News headline image
Market Currents: Why Pick Stocks? ↗
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and... 
Via Talk Markets
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.